RECOMBIVAX HB

This brand name is authorized in United States. It is also authorized in Brazil, Canada.

Active ingredients

The drug RECOMBIVAX HB contains one active pharmaceutical ingredient (API):

`1`	Hepatitis B, purified antigen UNII `XL4HLC6JH6` - HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN
	Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.
	Read more about Hepatitis B, purified antigen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RECOMBIVAX HB Suspension for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BC01	Hepatitis B, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	525502601156415, 525502602152413
CA	Health Products and Food Branch	02243676, 02245977
US	FDA, National Drug Code	0006-4093, 0006-4094, 0006-4981, 0006-4992, 0006-4995, 50090-1716, 50090-1719, 50090-1849

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.